Eastbourne District General Hospital

Abstract The genetic make-up of an individual contributes to the susceptibility and response to viral infection. Although environmental, clinical and social factors have a role in the chance of exposure to SARS-CoV-2 and the severity of COVID-19 1,2 , host genetics may also be important. Identifying host-specific genetic factors may reveal biological mechanisms of therapeutic relevance and clarify causal relationships of modifiable environmental risk factors for SARS-CoV-2 infection and outcomes. We formed a global network of researchers to investigate the role of human genetics in SARS-CoV-2 infection and COVID-19 severity. Here we describe the results of three genome-wide association meta-analyses that consist of up to 49,562 patients with COVID-19 from 46 studies across 19 countries. We report 13 genome-wide significant loci that are associated with SARS-CoV-2 infection or severe manifestations of COVID-19. Several of these loci correspond to previously documented associations to lung or autoimmune and inflammatory diseases 3–7 . They also represent potentially actionable mechanisms in response to infection. Mendelian randomization analyses support a causal role for smoking and body-mass index for severe COVID-19 although not for type II diabetes. The identification of novel host genetic factors associated with COVID-19 was made possible by the community of human genetics researchers coming together to prioritize the sharing of data, results, resources and analytical frameworks. This working model of international collaboration underscores what is possible for future genetic discoveries in emerging pandemics, or indeed for any complex human disease.

The neuropsychological performance of 85 women with early stage breast cancer scheduled for chemotherapy, 43 women scheduled for endocrine therapy and/or radiotherapy and 49 healthy control subjects was assessed at baseline (T1), postchemotherapy (or 6 months) (T2) and at 18 months (T3). Repeated measures analysis found no significant interactions or main effect of group after controlling for age and intelligence. Using a calculation to examine performance at an individual level, reliable decline on multiple tasks was seen in 20% of chemotherapy patients, 26% of nonchemotherapy patients and 18% of controls at T2 (18%, 14 and 11%, respectively, at T3). Patients who had experienced a treatment-induced menopause were more likely to show reliable decline on multiple measures at T2 (OR=2.6, 95% confidence interval (CI) 0.823-8.266 P=0.086). Psychological distress, quality of life measures and self-reported cognitive failures did not impact on objective tests of cognitive function, but were significantly associated with each other. The results show that a few women experienced objective measurable change in their concentration and memory following standard adjuvant therapy, but the majority were either unaffected or even improve over time.

BACKGROUND: Progress in characterising the humoral immune response to Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist. Assessment of the full range of evidence generated to date to understand the characteristics of the antibody response, its dynamics over time, its determinants and the immunity it confers will have a range of clinical and policy implications for this novel pathogen. This review comprehensively evaluated evidence describing the antibody response to SARS-CoV-2 published from 01/01/2020-26/06/2020. METHODS: Systematic review. Keyword-structured searches were carried out in MEDLINE, Embase and COVID-19 Primer. Articles were independently screened on title, abstract and full text by two researchers, with arbitration of disagreements. Data were double-extracted into a pre-designed template, and studies critically appraised using a modified version of the Public Health Ontario Meta-tool for Quality Appraisal of Public Health Evidence (MetaQAT) tool, with resolution of disagreements by consensus. Findings were narratively synthesised. RESULTS: 150 papers were included. Most studies (113 or 75%) were observational in design, were based wholly or primarily on data from hospitalised patients (108, 72%) and had important methodological limitations. Few considered mild or asymptomatic infection. Antibody dynamics were well described in the acute phase, up to around three months from disease onset, but the picture regarding correlates of the antibody response was inconsistent. IgM was consistently detected before IgG in included studies, peaking at weeks two to five and declining over a further three to five weeks post-symptom onset depending on the patient group; IgG peaked around weeks three to seven post-symptom onset then plateaued, generally persisting for at least eight weeks. Neutralising antibodies were detectable within seven to 15 days following disease onset, with levels increasing until days 14-22 before levelling and then decreasing, but titres were lower in those with asymptomatic or clinically mild disease. Specific and potent neutralising antibodies have been isolated from convalescent plasma. Cross-reactivity but limited cross-neutralisation with other human coronaviridae was reported. Evidence for protective immunity in vivo was limited to small, short-term animal studies, showing promising initial results in the immediate recovery phase. CONCLUSIONS: Literature on antibody responses to SARS-CoV-2 is of variable quality with considerable heterogeneity of methods, study participants, outcomes measured and assays used. Although acute phase antibody dynamics are well described, longer-term patterns are much less well evidenced. Comprehensive assessment of the role of demographic characteristics and disease severity on antibody responses is needed. Initial findings of low neutralising antibody titres and possible waning of titres over time may have implications for sero-surveillance and disease control policy, although further evidence is needed. The detection of potent neutralising antibodies in convalescent plasma is important in the context of development of therapeutics and vaccines. Due to limitations with the existing evidence base, large, cross-national cohort studies using appropriate statistical analysis and standardised serological assays and clinical classifications should be prioritised.

BACKGROUND: Understanding the T cell response to SARS-CoV-2 is critical to vaccine development, epidemiological surveillance and disease control strategies. This systematic review critically evaluates and synthesises the relevant peer-reviewed and pre-print literature published from 01/01/2020-26/06/2020. METHODS: For this systematic review, keyword-structured literature searches were carried out in MEDLINE, Embase and COVID-19 Primer. Papers were independently screened by two researchers, with arbitration of disagreements by a third researcher. Data were independently extracted into a pre-designed Excel template and studies critically appraised using a modified version of the MetaQAT tool, with resolution of disagreements by consensus. Findings were narratively synthesised. RESULTS: 61 articles were included. 55 (90%) studies used observational designs, 50 (82%) involved hospitalised patients with higher acuity illness, and the majority had important limitations. Symptomatic adult COVID-19 cases consistently show peripheral T cell lymphopenia, which positively correlates with increased disease severity, duration of RNA positivity, and non-survival; while asymptomatic and paediatric cases display preserved counts. People with severe or critical disease generally develop more robust, virus-specific T cell responses. T cell memory and effector function has been demonstrated against multiple viral epitopes, and, cross-reactive T cell responses have been demonstrated in unexposed and uninfected adults, but the significance for protection and susceptibility, respectively, remains unclear. CONCLUSION: A complex pattern of T cell response to SARS-CoV-2 infection has been demonstrated, but inferences regarding population level immunity are hampered by significant methodological limitations and heterogeneity between studies, as well as a striking lack of research in asymptomatic or pauci-symptomatic individuals. In contrast to antibody responses, population-level surveillance of the T cell response is unlikely to be feasible in the near term. Focused evaluation in specific sub-groups, including vaccine recipients, should be prioritised.

ECG loop recorders have a retrospective (loop) memory which continuously records and deletes the patient's ECG. They include a patient-activation function that allows the patient to activate ECG storage as a result of symptoms and an auto-activation feature that allows the capture of arrhythmic events without relying on patient compliance or perception of symptoms. Loop recorder devices can be both implantable (ILR) and external (ELR). Table 1 summarizes the characteristics of the most common diagnostic loop recorders. The retrospective memory differentiates loop recorders from prospective-only event recorders. While event recorders have some usefulness in patients with intermittent palpitations, they have no indication to detect syncope. Most common implantable and external loop recorders a, coming soon (not yet available); b, mobile cardiac outpatient telemetry; c, depends on Memory Card capacity. *Monitoring duration is determined by the battery longevity for implantable devices and by average maximum patients' compliance for external devices. Most common implantable and external loop recorders a, coming soon (not yet available); b, mobile cardiac outpatient telemetry; c, depends on Memory Card capacity. *Monitoring duration is determined by the battery longevity for implantable devices and by average maximum patients' compliance for external devices. Knowledge of what occurs during a spontaneous event is the ideal gold standard for evaluation. Patients with infrequent short-duration transient symptoms, recurring over weeks or months, are unlikely to be diagnosed by conventional Holter monitoring, since the likelihood of symptom-ECG correlation is very low. Consideration should be given to patient-activated event recording in such patients, but this technique has important limitations that might prevent a successful ECG recording of the event, especially for those with syncope, as it implies the activation of recording by the patients once the patient has already recovered consciousness. In such circumstances, consideration should be given to implantable and external ECG loop recorders. It is likely that loop recorders will become increasingly important, and their use will increasingly be appropriate instead of, or before, many current conventional investigations. This early loop recorder approach implies, on the one hand, the need for careful initial risk stratification in order to exclude from such a strategy patients with potential life-threatening conditions that require immediate hospitalization or intensive evaluation and treatment. On the other hand, as a general rule ECG loop recorders are indicated only when there is a high pre-test probability of identifying an heart rhythm abnormality responsible of symptoms. These conditions will be discussed in the document. Ultimately, technology may allow recording of multiple signals in addition to the ECG (e.g. blood flow or pressure, EEG, etc.) and the automatic immediate wireless transmission of pertinent data to a central monitoring station. Such advances will permit greater emphasis on the documenting and characterizing of spontaneous episodes. Conversely, they will result in less reliance for current diagnostic testing techniques that are largely designed to assess susceptibility to the provocation of syncope or palpitations in the laboratory. The Task Force has classified and ranked the usefulness or efficacy of the recommended procedure and/or treatments and the level of evidence as indicated in the tables below: The Task force was unable to give formal recommendations for non-established indications, i.e. atrial fibrillation and risk stratification, due to the lack of sufficient trial-based evidence. In these fields, loop recorders remain very interesting research tools. Clinical evaluation is enough to establish a likely mechanism of syncope in the majority of patients Exclude high-risk patients, i.e. those with a clear indication for ICD, pacemaker, or other treatments independent of a definite diagnosis of the cause of syncope Be aware that the pre-test selection of the patients influences the subsequent findings. Include patients with a high likelihood of arrhythmic events Include patients with a high probability of recurrence of syncope in a reasonable time period Due to the unpredictability of syncope recurrence, be prepared to wait for a substantial time before obtaining such a correlation Your ideal goal should be to obtain a correlation ECG and are Clinical evaluation is enough to establish a likely mechanism of syncope in the majority of patients Exclude high-risk patients, i.e. those with a clear indication for ICD, pacemaker, or other treatments independent of a definite diagnosis of the cause of syncope Be aware that the pre-test selection of the patients influences the subsequent findings. Include patients with a high likelihood of arrhythmic events Include patients with a high probability of recurrence of syncope in a reasonable time period Due to the unpredictability of syncope recurrence, be prepared to wait for a substantial time before obtaining such a correlation Your ideal goal should be to obtain a correlation ECG and are is in the general and of the general of an of of during of one of with a the of and increasingly the of In the for the of syncope a from events in to in 1 only of these in a and an some evaluation. of this can be in the the of this the of the of syncope recurrence the duration of the loop weeks for external and to for implantable for an appropriate selection of the for these diagnostic of of and their are the of Table recurrence in patients without heart and and the probability in the of patients in the 1 and by syncope or syncope. Conversely, of and or of heart have or on probability of syncope recurrence and are for the selection of the the of heart the likelihood of of an which will have of patients with of from and of patients with of from and of patients with diagnosis and risk the of during a a of patients with diagnosis and risk the of during a a of patients with diagnosis and risk the of during the a a of patients with diagnosis and risk the of during the a a In the initial the was for diagnosis in patients with syncope the of conventional In a of patients, correlation was in of patients a of of data from for a of patients with syncope the of a conventional that a correlation syncope and ECG was in patients of these in the time of the event, and no 1 In data from was less likely to be with an syncope some to be an for syncope in a diagnosis is only during that is for syncope. The diagnostic of was by the to a in to of the patients of the the and automatic of the and by in the most devices. in patients with syncope and implantable loop recorder the of conventional and in patients with syncope and implantable loop recorder early initial evaluation. The majority of ECG the time of with many events The majority of The correlation of a ECG with a spontaneous syncope can be as the gold that this is in episodes. are data on of in the data from and patients by of due to an in of these the during the was the that during the syncope. These data in the majority of patients, the or of an during the syncope can be a diagnostic and a can be the of and the data be as the initial in patients with syncope, it that the might become the standard to be when an arrhythmic cause of syncope is but to allow an treatment. are in which to be These when was in patients with syncope the of the conventional and when was in patients with syncope in an early the initial evaluation 1 In both a due to or due to on average in duration was the most syncope in the of cardiac Patients with in a is likely a in these patients, a the most is an intermittent which was by in of the events a of these in the in which an intermittent that was by was in of the these patients only and of the patients the of the mechanism of syncope in those patients have recurrence during the Patients with definite heart in an is likely a Patients with when the of the mechanism of spontaneous syncope is to a In patients in a cardiac cause of syncope is due to heart or in data on patients from a diagnosis was in of of these a or the time of the event, and no but of patients have a likely diagnosis of syncope the initial or during in order to capture an event when cardiac be by the and unpredictability of symptoms and lack of of syncope Patients in was but the has and in patients with in order to detect cardiac that require Patients with and of in order to exclude an arrhythmic cause of In patients with to establish the of the event The diagnostic was in patients with and without heart in the of in the of and in the of While patients with and without heart of syncope recurrence, mechanism was patients with heart and and patients without heart or no on the other the patients with only arrhythmic patients with heart an The diagnostic was in the In one the patients a syncope recurrence those and likely to have an time of syncope of with was by that of patients with syncope the of a conventional to of patients for evaluation to a syncope have an indication for the need for in the general was to be this to the indication for patients those by syncope, of syncope in or and the need for to This is of since a correlation with the syncope allow the use of or as of the mechanism of syncope, to the diagnostic and/or to without for of a with the patient in order to the of the of a In the of the patients with an during in patients and in the during on the in patients without during an when they a in the of the patients with patients an as or and of the during the on the in of patients without during a during the syncope. was with classified as in the In the patients with the time of events and the other of In the patients with only a syncope and the no the time of the syncope. the of a during or has a for the diagnosis of the mechanism of syncope. In the of an or a patient-activated or the mechanism of syncope, the strategy of these as diagnostic findings. The of these is in and by with other of ECG monitoring and in current the of an or a in the the diagnostic have by to and diagnosis have on average by in of diagnosis by of syncope. this force that these for and are both largely auto-activation feature the diagnostic this feature can be by the of and the of of storage in include to in during both rhythm and by transient of ECG to and of a of from patients with the that a of of by the and of patients one or episodes. most of these can be they can with of The of is data the of are of is a of the risk of that with This which can in the or during the was in a of 1 to of the of the of and the of rhythm with the the time of syncope, the have a that the in order to an for and Table 1 was the most that was in of was in of or rhythm was in of and was in of This has become and by The has some which are to of arrhythmic syncope and have and In and the of most by due to or by due to that the syncope is In the of due to with in of the as in In and a cardiac is responsible for syncope. In the other in which no is the of syncope of the lack of recording of blood the of heart and/or the time of syncope a or activation of the and a The of spontaneous syncope or initial by by with in with in with in of heart or for of heart for or rhythm of heart and heart or in heart in heart but and but and of heart and heart fibrillation or initial by by with in with in with in of heart or for of heart for or rhythm of heart and heart or in heart in heart but and but and of heart and heart fibrillation The of spontaneous syncope or initial by by with in with in with in of heart or for of heart for or rhythm of heart and heart or in heart in heart but and but and of heart and heart fibrillation or initial by by with in with in with in of heart or for of heart for or rhythm of heart and heart or in heart in heart but and but and of heart and heart fibrillation In the initial the was as in the evaluation of syncope have a correlation the of and and the ECG the time of spontaneous syncope In other the and of some of the most important for diagnosis on their in the diagnostic the diagnostic of ECG monitoring external loop have an early of the soon in an initial of the diagnostic patients with syncope to testing with external loop recorder and and testing or to monitoring with the The that a strategy of of the loop recorder in an initial of the is likely to a diagnosis conventional testing during a patients high risk of life-threatening as those with an of These in the in patients a to the or conventional and The patients a probability of a diagnosis when with the conventional during a of in the and in the conventional early the initial evaluation was in the in patients with syncope. Patients with heart diagnosis was in of the patients during a of the patients of these due to arrhythmic due to and due to to syncope in and in In the that early can be in the initial of the diagnostic that patients risk of life-threatening events are to the of syncope of the of the patients risk require immediate hospitalization and intensive evaluation can be the initial evaluation Table In these risk are an strategy can be in the patients risk for arrhythmic syncope have a of syncope of high risk of or high of which can of a In the less evaluation is sufficient to establish a likely mechanism of syncope in the majority of patients and no is Patients risk for arrhythmic syncope are for the of the usefulness of is largely as a general is indicated when the probability of syncope recurrence during the longevity of the battery is and when the of a correlation is for the patients with an indication for implantable to should this The monitoring function of the can be to the mechanism of syncope. the patients with and should an which should be only the of a the patients with or that an intermittent should monitoring and an should be the of a high-risk that require immediate hospitalization or early intensive evaluation as appropriate on syncope in which there is a clear indication for or of a definite diagnosis of the cause of syncope to or or or Clinical or ECG an arrhythmic during or the time of syncope of duration or in the of or with in in and of in which there is a clear indication for or of a definite diagnosis of the cause of syncope to or or or Clinical or ECG an arrhythmic during or the time of syncope of duration or in the of or with in in and of high-risk that require immediate hospitalization or early intensive evaluation as appropriate on syncope in which there is a clear indication for or of a definite diagnosis of the cause of syncope to or or or Clinical or ECG an arrhythmic during or the time of syncope of duration or in the of or with in in and of in which there is a clear indication for or of a definite diagnosis of the cause of syncope to or or or Clinical or ECG an arrhythmic during or the time of syncope of duration or in the of or with in in and of flow is in The recommended and diagnostic are in the loop recorder in the of transient of is the In the on a the patients to an diagnostic and treatments conventional a only be to a of patients, the a in events with of is the most the time of syncope recurrence, cardiac is the most in In the initial to was in of patients In data of patients from a was in of patients of those an This from in patients with syncope to in the patients with a data are on the subsequent In cardiac syncope in patients with but prevent the of syncope. In the the of syncope from in the of patients without to in the patients with a risk In the of the of a cardiac pacemaker, syncope from to in patients with or ECG of the and from to in the syncope In data of patients from an and in 1 and of the patients and atrial in in patients with atrial fibrillation and The of for diagnosis of and infrequent symptoms such as syncope is that the patients continuously external in order to activate loop The to have in patients with spontaneous symptoms are likely to This time is the maximum that a patient can duration diagnostic can be the that documenting an ECG during will the mechanism of syncope. are to those for but the patient selection depends on the of the probability of recurrence and diagnostic are the as for In to a diagnostic conventional evaluation or Holter monitoring but syncope over or the for are to patients with high probability of recurrence in a very The diagnostic in such patients is low. In one patients with a of during the and no heart only 1 be by which In patients with a of during a diagnosis was in a diagnosed in loop recorders to be when symptoms in addition to and less are in order to exclude an arrhythmic cause of symptoms. in an correlation was in of patients but an was in only 1 patient it be in the other In a a correlation was in and of correlation was in of these and when an was in the a of are It should be in of of correlation with their is and monitoring should be diagnosis is by In an early of evaluation of patients with syncope of of high-risk that require immediate hospitalization or intensive i.e. those in the Table and likely recurrence battery longevity of the of evidence In high-risk patients in a evaluation in Table a cause of syncope or to of evidence assess the of before on cardiac in patients with or syncope with or of evidence In patients with of in order to exclude an arrhythmic mechanism of evidence of and of arrhythmic and of high-risk that require immediate hospitalization or intensive i.e. those in Table of evidence and are diagnostic correlation syncope and an or is of evidence the of such of or or a for during patients or atrial or for atrial or are of evidence and exclude an arrhythmic cause when there is no correlation syncope and rhythm of evidence without as those of evidence those of evidence of of evidence In an early of evaluation of patients with syncope of of high-risk that require immediate hospitalization or intensive i.e. those in the Table and likely recurrence battery longevity of the of evidence In high-risk patients in a evaluation in Table a cause of syncope or to of evidence assess the of before on cardiac in patients with or syncope with or of evidence In patients with of in order to exclude an arrhythmic mechanism of evidence of and of arrhythmic and of high-risk that require immediate hospitalization or intensive i.e. those in Table of evidence and are diagnostic correlation syncope and an or is of evidence the of such of or or a for during patients or atrial or for atrial or are of evidence and exclude an arrhythmic cause when there is no correlation syncope and rhythm of evidence without as those of evidence those of evidence of of evidence are for palpitations for syncope evaluation are less indicated records may be only when symptoms enough to allow the patient to activate the recorder The diagnostic of loop recorders is are for palpitations for syncope evaluation are less indicated records may be only when symptoms enough to allow the patient to activate the recorder The diagnostic of loop recorders is a very common for which They may be due to cardiac from atrial and to atrial and or to to such as and In especially in patients with infrequent symptoms, a diagnosis is to establish in of careful evaluation that standard ECG and Holter The usefulness of event recorders which are or by the patient is by the that they are unable to detect the mechanism of of the and by the lack of automatic the of palpitations a correlation symptoms and ECG can be by the of and patients with palpitations can be on high-risk patients may need hospitalization and to rule life-threatening are in Table on On the other hand, some patients with and symptoms and no cardiac can be and without a diagnosis be the patients risk with and or symptoms are the for loop recorders. They are to since they are of recording retrospective and ECG by the they allow automatic recording of is monitoring be for patients with recurrence of palpitations the ideal can be for a as as event when the duration of is enough to allow the of the by the patient In in which patients with recurrence of palpitations, as as event recorders a diagnostic of to that of conventional Holter to the of palpitations in patients, the most are atrial and and atrial and are less palpitations are for for syncope evaluation. In a of patients by palpitations, or syncope, with an of in and of the correlation was in those with palpitations, and syncope. loop due to their and a in patients with palpitations when with those with syncope. They may be in patients with infrequent palpitations with when other result are on the use of in patients with In the patients with infrequent and Patients to conventional strategy Holter a period of ECG monitoring with an external and or to with diagnosis was in patients in the conventional strategy and in in the the initial the diagnosis in the was in the conventional strategy a diagnosis was patients for in patients with arrhythmic diagnosis with pacemaker, or The and for and are in Table and for event and from and for event and from for syncope, the gold standard for loop recorder use is the correlation ECG and symptoms. The of the technique is high when an is during symptoms. rhythm during palpitations an arrhythmic The of loop recorders is and depends on that include monitoring technique and of symptoms, and patient and are diagnostic when a correlation and an is level of evidence and exclude an arrhythmic cause when there is no correlation and rhythm level of evidence and are diagnostic when a correlation and an is level of evidence and exclude an arrhythmic cause when there is no correlation and rhythm level of evidence is a correlation of symptoms with atrial fibrillation especially rhythm is which evaluation of the of are potential for in to the efficacy of rhythm in rhythm when from is the to the of is by intermittent monitoring monitoring by implantable devices the of but it is by and are for of can diagnostic are The of some with devices are The of Loop to and has yet to be is a correlation of symptoms with atrial fibrillation especially rhythm is which evaluation of the of are potential for in to the efficacy of rhythm in rhythm when from is the to the of is by intermittent monitoring monitoring by implantable devices the of but it is by and are for of can diagnostic are The of some with devices are The of Loop to and has yet to be While techniques are for of ECG monitoring the in the efficacy of rhythm in to the efficacy of rhythm is to have that the and duration of are and a there is a correlation of symptoms with without or symptoms, in In some patients, palpitations due to or may to and of may the perception of the In as as in the of was to during and patients of a during a Holter is a correlation the symptoms and of from are potential for a of rhythm can be with or intermittent monitoring Holter to and event recorders with or without loop In rhythm the of is a and a for a of it is to symptoms with ECG especially when the of symptoms is potential are the for in patients to and the evaluation of the efficacy of the rhythm the of these indication of has yet to be that the risk is by the of and In one but was with that the risk by can be by with of events the to duration of with or duration from to with or duration with It is that the likelihood of as as with the duration of the monitoring the duration of Holter from to the of approach is the use of the for ECG recording recording during of symptoms. both and may be Most the ECG or some the data on a memory The is to the and is only the for the ECG recording time of The of the it for that are to assess of the event recorder is to on the duration of episodes. for of 1 monitoring as Holter ECG the current on rhythm in to detect by Holter monitoring or ECG In patients should be with an event this one has to that with the monitoring no of will be loop recorder is ideal for of when it to an event recorder or for ECG of that are with symptoms such as syncope. ECG recording is to the or by the require of on the for activation of the loop This to be only by patients for a period of 1 with a maximum of have indicated that compliance is when patients are to use for Such a recording is for of rhythm in patients with the no for this in patients, the may to symptoms with of over a period of with monitoring is from of data in implantable devices such as and with an atrial They allow of by the and duration of episodes. of their duration or symptoms can be of data has that intermittent Holter recording with monitoring recurrence the of the data depends on the of due to and atrial may of and duration of episodes. In an of of to be from due to or are for of only monitoring is to the of and episodes. of the correlation strategy and the of has by intermittent with monitoring by that of have with 1 Holter this most of recurrence is only in the of or correlation strategy and the of atrial fibrillation loop recorders a in patients with infrequent symptoms and The an of monitoring of heart rhythm and use in patients to of In an of patients, of patient-activated for a of in most in a symptoms and was of ECG to be from due to The of the is a lack of automatic that of and the no in The of the Table 1 automatic on rhythm the have to the of this to detect This of the with Holter In patients, the is designed to the of by the with standard of and especially are patients with function and patients with have a high risk of are for research and of cardiac The usefulness of to and in patients has yet to be have a potential in identifying the correlation symptoms and in high-risk patients by ECG or and and especially are patients with function and patients with have a high risk of are for research and of cardiac The usefulness of to and in patients has yet to be have a potential in identifying the correlation symptoms and in high-risk patients by ECG or and and research ECG loop recorders has on patients, especially patients with syncope, documenting the arrhythmic of symptoms. The a research for in patient and was designed to the and of cardiac in patients with In this and/or in patients during a of these The a of duration and was by and was with an risk of cardiac during the in documenting events as a of risk stratification weeks

Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined<5 × 10(-8)) and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine-cytokine pathways, for which relevant therapies exist.

Abstract Adoptive cell transfer using chimeric antigen receptors (CAR) has emerged as one of the most promising new therapeutic modalities for patients with relapsed or refractory B-cell malignancies. Thus far, results in patients with advanced solid tumors have proven disappointing. Constitutive tonic signaling in the absence of ligand is an increasingly recognized complication when deploying these synthetic fusion receptors and can be a cause of poor antitumor efficacy, impaired survival, and reduced persistence in vivo. In parallel, ligand-dependent tonic signaling can mediate toxicity and promote T-cell anergy, exhaustion, and activation-induced cell death. Here, we review the mechanisms underpinning CAR tonic signaling and highlight the wide variety of effects that can emerge after making subtle structural changes or altering the methodology of CAR transduction. We highlight strategies to prevent unconstrained tonic signaling and address its deleterious consequences. We also frame this phenomenon in the context of endogenous TCR tonic signaling, which has been shown to regulate peripheral tolerance, facilitate the targeting of foreign antigens, and suggest opportunities to coopt ligand-dependent CAR tonic signaling to facilitate in vivo persistence and efficacy. Mol Cancer Ther; 17(9); 1795–815. ©2018 AACR.

AIMS: Increasing evidence exists suggesting that biventricular pacing improves outcome and symptoms in severe heart failure if various selection criteria are fulfilled. It is unsure how many people might benefit from this therapy. Our aim was to provide such data. METHODS AND RESULTS: Over one calendar year all patients admitted to a large U.K. District General Hospital, that were classified with a diagnosis of heart failure, were audited. The selection criteria were; (1) severe heart failure (NYHA class III or IV), (2) heart failure due to a dilated cardiomyopathy, (3) QRS duration greater than 120 ms or (4) the presence of a bundle branch block pattern. Subjects were divided into those in sinus rhythm to determine those who would be suitable for atrially synchronized biventricular pacing and those with an abnormally long PR interval (>210 ms) who might additionally benefit from improved atrioventricular synchrony. 1042 patients were coded with heart failure. 721 fulfilled diagnostic criteria and were studied. 202 (28%) had severe heart failure, 178 (25%) had a QRS of at least 120 ms, 437 (61%) had an ischaemic cardiomyopathy, 176 (24%) an idiopathic cardiomyopathy and 433 (60%) were in sinus rhythm. Overall mortality at the time of census was 29%. 43 patients were suitable for biventricular pacing with a further 29 atrial patients fibrillation who might benefit from biventricular pacing alone. CONCLUSION: Using our criteria, approximately 10% of an unselected group of heart failure admitted to a typical U.K. district general hospital over a calendar year would be appropriate for biventricular pacing. This represents a large number of patients who might derive benefit from this new therapy.

AIMS: Implantable loop recorders (ILR) provide an opportunity to record ECG data from a spontaneous syncopal event. We conducted a randomized study to investigate the impact of the Reveal Plus ILR on an unselected population of patients with recurrent syncope. Initial follow-up (at least 6 months) did not demonstrate a reduction in syncopal events or an improvement in quality of life. We report the planned extension of follow-up to 18 months. METHODS AND RESULTS: All patients presenting acutely with recurrent unexplained syncope over a 16-month period, following a basic clinical work-up, were randomized to receive the ILR or conventional investigation and management. A total of 421 patients presented, 201 were eligible, median age 74, (IQ range 61-81) 54% female, with median syncopes 3 (IQ range 2-6). Median follow-up 17 months (IQ range 9-23). 42 (43%) of ILR patients and 8 (6%) of conventional patients received an ECG diagnosis (hazard ratio 6.53, 95% CI 3.73-11.4, P<0.001). Time to second syncope was significantly longer for ILR patients, although of borderline significance (P=0.04). A greater variety of diagnoses and treatments were seen in ILR patients. ILR patients had fewer post-randomization investigations and fewer days in hospital; however, cost savings were not statistically significant. There was improved quality of life in the ILR group (visual analogue scales, P=0.03) for general wellbeing. Overall mortality was 12% with no difference between the two groups. CONCLUSION: Investigation by the ILR significantly increases the diagnostic rate and ECG directed treatments in a typical unselected syncopal population. Long-term follow-up has demonstrated a significant subsequent reduction in syncopal events with improved quality of life.

Abstract Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown 1 to be highly efficient for discovery of genetic associations 2 . Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group 3 . Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a strong focus on severe and critical disease: ISARIC4C (676 cases) and the SCOURGE consortium (5,934 cases). To put these results in the context of existing work, we conduct a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data. We find 49 genome-wide significant associations, of which 16 have not been reported previously. To investigate the therapeutic implications of these findings, we infer the structural consequences of protein-coding variants, and combine our GWAS results with gene expression data using a monocyte transcriptome-wide association study (TWAS) model, as well as gene and protein expression using Mendelian randomization. We identify potentially druggable targets in multiple systems, including inflammatory signalling ( JAK1 ), monocyte–macrophage activation and endothelial permeability ( PDE4A ), immunometabolism ( SLC2A5 and AK5 ), and host factors required for viral entry and replication ( TMPRSS2 and RAB2A ).

There have been significant advances in the field of echocardiography with the introduction of a number of new techniques into standard clinical practice. Consequently, a 'standard' echocardiographic examination has evolved to become a more detailed and time-consuming examination that requires a high level of expertise. This Guideline produced by the British Society of Echocardiography (BSE) Education Committee aims to provide a minimum dataset that should be obtained in a comprehensive standard echocardiogram. In addition, the layout proposes a recommended sequence in which to acquire the images. If abnormal pathology is detected, additional views and measurements should be obtained with reference to other BSE protocols when appropriate. Adherence to these recommendations will promote an increased quality of echocardiography and facilitate accurate comparison of studies performed either by different operators or at different departments.

Oomycetes are a diverse group of eukaryotes in terrestrial, limnic and marine habitats worldwide and include several devastating plant pathogens, for example Phytophthora infestans (potato late blight). The cytochrome c oxidase subunit 2 gene (cox2) has been widely used for identification, taxonomy and phylogeny of various oomycete groups. However, recently the cox1 gene was proposed as a DNA barcode marker instead, together with ITS rDNA. The cox1 locus has been used in some studies of Pythium and Phytophthora, but has rarely been used for other oomycetes, as amplification success of cox1 varies with different lineages and sample ages. To determine which out of cox1 or cox2 is best suited as a universal oomycete barcode, we compared these two genes in terms of (i) PCR efficiency for 31 representative genera, as well as for historic herbarium specimens, and (ii) sequence polymorphism, intra- and interspecific divergence. The primer sets for cox2 successfully amplified all oomycete genera tested, while cox1 failed to amplify three genera. In addition, cox2 exhibited higher PCR efficiency for historic herbarium specimens, providing easier access to barcoding-type material. Sequence data for several historic type specimens exist for cox2, but there are none for cox1. In addition, cox2 yielded higher species identification success, with higher interspecific and lower intraspecific divergences than cox1. Therefore, cox2 is suggested as a partner DNA barcode along with ITS rDNA instead of cox1. The cox2-1 spacer could be a useful marker below species level. Improved protocols and universal primers are presented for all genes to facilitate future barcoding efforts.

Nineteen patients with high-risk myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) received fludarabine, cytarabine, granulocyte-colony stimulating factor (G-CSF), and idarubicin chemotherapy (de novo MDS/MDS-AML, nine; relapsed/refractory MDS/AML, seven; therapy-related MDS, three). Median age was 44 years and median disease duration 10 months. 16/19 (84%) patients had abnormal cytogenetics with seven (37%) harbouring abnormalities of chromosome 7. 18/19 (94.7%) patients responded to FLAG-idarubicin with 12 (63%) achieving complete remission (CR) (< 5% blasts and normal cytogenetics). 7/9 (78%) patients with de novo MDS/MDS-AML achieved CR compared to 5/10 (50%) with alternative diagnoses. Response was associated with age < 50 years, disease duration < 3 months, and cytogenetics other than abnormalities of chromosome 7. Haemopoietic regeneration was rapid in most patients and there were no toxic deaths. Nine patients received a second course of chemotherapy, three have proceeded to allogeneic bone marrow transplant and three to autologous blood stem cell/bone marrow transplantation. Follow-up is short (median 10 months). 12/19 (63%) patients remain alive and 5/12 (42%) have relapsed at a median 5 months following CR achievement. FLAG-idarubicin was well tolerated. High rates of morphological and cytogenetic remission, especially in de novo MDS, offer a window of opportunity for assessment of autologous BMT in this group of diseases where no treatment except alloBMT has led to prolongation of survival.

Utilizing T cells expressing chimeric antigen receptors (CARs) to identify and attack solid tumors has proven challenging, in large part because of the lack of tumor-specific targets to direct CAR binding. Tumor selectivity is crucial because on-target, off-tumor activation of CAR T cells can result in potentially lethal toxicities. This study presents a stringent hypoxia-sensing CAR T cell system that achieves selective expression of a pan-ErbB-targeted CAR within a solid tumor, a microenvironment characterized by inadequate oxygen supply. Using murine xenograft models, we demonstrate that, despite widespread expression of ErbB receptors in healthy organs, the approach provides anti-tumor efficacy without off-tumor toxicity. This dynamic on/off oxygen-sensing safety switch has the potential to facilitate unlimited expansion of the CAR T cell target repertoire for treating solid malignancies.

The scale of the COVID-19 pandemic means that a significant number of patients who have previously been infected with SARS-CoV-2 will require surgery. Given the potential for multisystem involvement, timing of surgery needs to be carefully considered to plan for safe surgery. This consensus statement uses evidence from a systematic review and expert opinion to highlight key principles in the timing of surgery. Shared decision-making regarding timing of surgery after SARS-CoV-2 infection must account for severity of the initial infection; ongoing symptoms of COVID-19; comorbid and functional status; clinical priority and risk of disease progression; and complexity of surgery. For the protection of staff, other patients and the public, planned surgery should not be considered during the period that a patient may be infectious. Precautions should be undertaken to prevent pre- and peri-operative infection, especially in higher risk patients. Elective surgery should not be scheduled within 7 weeks of a diagnosis of SARS-CoV-2 infection unless the risks of deferring surgery outweigh the risk of postoperative morbidity or mortality associated with COVID-19. SARS-CoV-2 causes either transient or asymptomatic disease for most patients, who require no additional precautions beyond a 7-week delay, but those who have persistent symptoms or have been hospitalised require special attention. Patients with persistent symptoms of COVID-19 are at increased risk of postoperative morbidity and mortality even after 7 weeks. The time before surgery should be used for functional assessment, prehabilitation and multidisciplinary optimisation. Vaccination several weeks before surgery will reduce risk to patients and might lessen the risk of nosocomial SARS-CoV-2 infection of other patients and staff. National vaccine committees should consider whether such patients can be prioritised for vaccination. As further data emerge, these recommendations may need to be revised, but the principles presented should be considered to ensure safety of patients, the public and staff.

We assessed the influence of the use of a tourniquet in total knee arthroplasty in a prospective, randomised study. After satisfying exclusion criteria, we divided 77 patients into two groups, one to undergo surgery with a tourniquet and one without. Both groups were well matched. The mean change in knee flexion in the group that had surgery without a tourniquet was significantly better at one week (p = 0.03) than in the other group, but movement was similar at six weeks and at four months. There was no significant difference in the surgical time, postoperative pain, need for analgesia, the volume collected in the drains, postoperative swelling, and the incidence of wound complications or of deep-venous thrombosis. We conclude that the use of a tourniquet is safe and that current practice can be continued.

We reviewed 231 patients who had undergone total knee replacement with an AGC (Biomet) implant over a period of 2.5 years. After applying exclusion criteria and with some loss to follow-up, there were 144 patients available for study. These were divided into two groups; those who had received intra-articular steroid in the 11 months before surgery and those who had not. There were three deep infections, all of which occurred in patients who had received a steroid injection. The incidence of superficial infection was not significantly different in the two groups. Five patients had undergone investigation for suspected deep infection because of persistent swelling or pain and all of these had received an intra-articular injection pre-operatively. We conclude that the decision to administer intra-articular steroids to a patient who may be a candidate for total knee replacement should not be taken lightly because of a risk of post-operative deep infection.

BACKGROUND: In patients presenting with new-onset heart failure of uncertain etiology, the role of coronary angiography (CA) is unclear. Although conventionally performed to differentiate underlying coronary artery disease from dilated cardiomyopathy, CA is associated with a risk of complications and may not detect an ischemic cause resulting from arterial recanalization or an embolic episode. In this study, we assessed the diagnostic accuracy of a cardiovascular magnetic resonance (CMR) protocol incorporating late gadolinium enhancement (LGE) and magnetic resonance CA as a noninvasive gatekeeper to CA in determining the etiology of heart failure in this subset of patients. METHODS AND RESULTS: One hundred twenty consecutive patients underwent CMR and CA. The etiology was ascribed by a consensus panel that used the results of the CMR scans. Similarly, a separate consensus group ascribed an underlying cause by using the results of CA. The diagnostic accuracy of both strategies was compared against a gold-standard panel that made a definitive judgment by reviewing all clinical data. The study was powered to show noninferiority between the 2 techniques. The sensitivity of 100%, specificity of 96%, and diagnostic accuracy of 97% for LGE-CMR were equivalent to CA (sensitivity, 93%; specificity, 96%; and diagnostic accuracy, 95%). As a gatekeeper to CA, LGE-CMR was also found to be a cheaper diagnostic strategy in a decision tree model when United Kingdom-based costs were assumed. The economic merits of this model would change, depending on the relative costs of LGE-CMR and CA in any specific healthcare system. CONCLUSION: This study showed that LGE-CMR is a safe, clinically effective, and potentially economical gatekeeper to CA in patients presenting with heart failure of uncertain etiology.

BACKGROUND: Syncope is a common, disabling symptom. The most useful data for diagnosing and managing syncope is the recording of physical parameters such as the ECG and blood pressure during a spontaneous event. Implantable loop recorders (ILR) provide an opportunity to record ECG data from a spontaneous event. The purpose of the Eastbourne Syncope Assessment Study (EaSyAS) was to investigate the impact of ILRs on an unselected population of syncopal patients presenting acutely to our institution. METHODS: All patients presenting acutely with recurrent, unexplained syncope over a 16-month period, were randomised after a basic clinical workup to receive the Reveal Plus ILR or conventional investigation. All patients were followed up for at least 6 months (mean 276+/-134 days) following randomisation. The primary outcome measure was time to ECG diagnosis. RESULTS: Four hundred twenty-one patients presented, 201 were eligible, median age 74 years (interquartile range 61-81 years), 54% female, with a median of three previous syncopes (IQ range 2-6). Thirty-three percent of ILR patients and 4% of conventional patients had an ECG diagnosis (hazard ratio 8.93, 95% CI 3.17-25.2, p < or = 0.0001). Introduction of ECG-directed therapy was quicker for ILR patients (hazard ratio 7.9, 95% CI 2.8-22.3, p < 0.0001). ILR patients had fewer post-randomisation investigations and fewer hospital days, resulting in a saving of costs, 406 UK pounds versus 1210 UK pounds (mean difference 809 UK pounds, 95% CI 123-2730 UK pounds). There was no difference in the number of subsequent syncopal episodes, mortality, or quality of life. CONCLUSIONS: LR significantly increased the rate of diagnosis in an unselected Western population with recurrent syncope. There was a significant decrease in the rates of hospitalisation and investigation in patients receiving an ILR.

ABSTRACT Window‐based Euler deconvolution is commonly applied to magnetic and sometimes to gravity interpretation problems. For the deconvolution to be geologically meaningful, care must be taken to choose parameters properly. The following proposed process design rules are based partly on mathematical analysis and partly on experience. The interpretation problem must be expressible in terms of simple structures with integer Structural Index (SI) and appropriate to the expected geology and geophysical source. The field must be sampled adequately, with no significant aliasing. The grid interval must fit the data and the problem, neither meaninglessly over‐gridded nor so sparsely gridded as to misrepresent relevant detail. The required gradient data (measured or calculated) must be valid, with sufficiently low noise, adequate representation of necessary wavelengths and no edge‐related ringing. The deconvolution window size must be at least twice the original data spacing (line spacing or observed grid spacing) and more than half the desired depth of investigation. The ubiquitous sprays of spurious solutions must be reduced or eliminated by judicious use of clustering and reliability criteria, or else recognized and ignored during interpretation. The process should be carried out using Cartesian coordinates if the software is a Cartesian implementation of the Euler deconvolution algorithm (most accessible implementations are Cartesian). If these rules are not adhered to, the process is likely to yield grossly misleading results. An example from southern Africa demonstrates the effects of poor parameter choices.